Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Novo Nordisk A/S
Filip K Knop; Vanita R Aroda; Ruben D do Vale; Thomas Holst-Hansen; Peter N Laursen; Julio Rosenstock; Domenica M Rubino; W Timothy Garvey; OASIS 1 Investigators